| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Microbubbles | 9 | 2021 | 18 | 2.550 |
Why?
|
| Myocardium | 13 | 2021 | 224 | 2.500 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 8 | 2019 | 81 | 2.220 |
Why?
|
| Hypoxia-Inducible Factor 1 | 4 | 2021 | 11 | 2.000 |
Why?
|
| Myocardial Infarction | 4 | 2021 | 221 | 1.930 |
Why?
|
| Heart | 10 | 2021 | 178 | 1.910 |
Why?
|
| Myocardial Ischemia | 3 | 2021 | 72 | 1.840 |
Why?
|
| Endothelium, Vascular | 8 | 2015 | 229 | 1.700 |
Why?
|
| Myocytes, Cardiac | 4 | 2019 | 165 | 1.550 |
Why?
|
| Transcription, Genetic | 9 | 2019 | 550 | 1.360 |
Why?
|
| Ultrasonics | 5 | 2011 | 12 | 1.300 |
Why?
|
| Atherosclerosis | 4 | 2021 | 131 | 1.180 |
Why?
|
| Gene Transfer Techniques | 4 | 2021 | 43 | 1.170 |
Why?
|
| Animals | 49 | 2022 | 14307 | 1.150 |
Why?
|
| Mice | 34 | 2022 | 5668 | 1.140 |
Why?
|
| Mice, Inbred C57BL | 14 | 2021 | 1530 | 1.100 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2021 | 79 | 1.080 |
Why?
|
| MicroRNAs | 2 | 2020 | 386 | 1.000 |
Why?
|
| Alternative Splicing | 2 | 2021 | 82 | 0.950 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2019 | 26 | 0.950 |
Why?
|
| Gene Expression Profiling | 5 | 2018 | 600 | 0.890 |
Why?
|
| Endothelin-1 | 4 | 2008 | 54 | 0.870 |
Why?
|
| Diabetic Angiopathies | 2 | 2015 | 20 | 0.860 |
Why?
|
| RNA, Messenger | 9 | 2020 | 1152 | 0.830 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2021 | 16 | 0.820 |
Why?
|
| Endothelial Cells | 7 | 2022 | 296 | 0.820 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2 | 2018 | 6 | 0.790 |
Why?
|
| Amphetamine-Related Disorders | 2 | 2019 | 63 | 0.770 |
Why?
|
| Mixed Function Oxygenases | 1 | 2020 | 29 | 0.760 |
Why?
|
| Up-Regulation | 3 | 2020 | 490 | 0.760 |
Why?
|
| Mice, Transgenic | 11 | 2021 | 608 | 0.740 |
Why?
|
| Cytoskeletal Proteins | 1 | 2020 | 97 | 0.710 |
Why?
|
| Methamphetamine | 2 | 2019 | 155 | 0.700 |
Why?
|
| Genome-Wide Association Study | 8 | 2020 | 271 | 0.680 |
Why?
|
| Cardiomyopathies | 3 | 2022 | 55 | 0.680 |
Why?
|
| Myocardial Contraction | 1 | 2018 | 47 | 0.680 |
Why?
|
| Gene Expression Regulation | 6 | 2019 | 968 | 0.670 |
Why?
|
| Pyruvate Kinase | 1 | 2018 | 7 | 0.660 |
Why?
|
| Neovascularization, Physiologic | 4 | 2021 | 70 | 0.650 |
Why?
|
| Male | 37 | 2023 | 18870 | 0.640 |
Why?
|
| Galectin 3 | 2 | 2015 | 26 | 0.640 |
Why?
|
| DNA-Binding Proteins | 2 | 2020 | 522 | 0.630 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2019 | 184 | 0.620 |
Why?
|
| Disease Models, Animal | 6 | 2020 | 1300 | 0.570 |
Why?
|
| Mice, Knockout | 9 | 2022 | 897 | 0.560 |
Why?
|
| Marfan Syndrome | 4 | 2022 | 4 | 0.560 |
Why?
|
| Plasmids | 4 | 2021 | 233 | 0.550 |
Why?
|
| Contrast Media | 6 | 2009 | 95 | 0.550 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2007 | 88 | 0.550 |
Why?
|
| Drug Delivery Systems | 2 | 2009 | 182 | 0.530 |
Why?
|
| Transfection | 3 | 2013 | 496 | 0.530 |
Why?
|
| Registries | 6 | 2022 | 330 | 0.510 |
Why?
|
| Loeys-Dietz Syndrome | 3 | 2023 | 3 | 0.500 |
Why?
|
| Cardiovascular Diseases | 6 | 2020 | 628 | 0.490 |
Why?
|
| Vehicle Emissions | 2 | 2011 | 21 | 0.470 |
Why?
|
| Gluconates | 1 | 2012 | 5 | 0.460 |
Why?
|
| Doxorubicin | 3 | 2022 | 80 | 0.450 |
Why?
|
| Hyperkalemia | 1 | 2012 | 13 | 0.450 |
Why?
|
| Aortic Aneurysm, Thoracic | 3 | 2017 | 6 | 0.450 |
Why?
|
| Cnidarian Venoms | 1 | 2012 | 23 | 0.440 |
Why?
|
| Cardiovascular System | 1 | 2012 | 30 | 0.440 |
Why?
|
| Heart Ventricles | 3 | 2016 | 121 | 0.440 |
Why?
|
| Humans | 38 | 2023 | 34853 | 0.430 |
Why?
|
| Air Pollutants | 2 | 2011 | 90 | 0.430 |
Why?
|
| Sonication | 3 | 2013 | 15 | 0.420 |
Why?
|
| Luciferases | 4 | 2005 | 62 | 0.400 |
Why?
|
| Inhalation Exposure | 1 | 2011 | 37 | 0.390 |
Why?
|
| Heart Valve Diseases | 4 | 2017 | 9 | 0.390 |
Why?
|
| Hypercholesterolemia | 1 | 2011 | 36 | 0.390 |
Why?
|
| Genetic Vectors | 5 | 2013 | 154 | 0.390 |
Why?
|
| Aortic Valve | 4 | 2017 | 25 | 0.380 |
Why?
|
| Aorta | 5 | 2017 | 161 | 0.380 |
Why?
|
| Particulate Matter | 1 | 2011 | 49 | 0.380 |
Why?
|
| Neovascularization, Pathologic | 3 | 2021 | 122 | 0.380 |
Why?
|
| Cell Hypoxia | 3 | 2019 | 55 | 0.380 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2011 | 298 | 0.350 |
Why?
|
| Heart Failure | 2 | 2011 | 230 | 0.350 |
Why?
|
| Signal Transduction | 7 | 2020 | 1802 | 0.340 |
Why?
|
| Cardiomegaly | 2 | 2011 | 39 | 0.330 |
Why?
|
| Endocytosis | 1 | 2009 | 104 | 0.330 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 605 | 0.330 |
Why?
|
| Quantitative Trait Loci | 3 | 2013 | 68 | 0.320 |
Why?
|
| Echocardiography | 6 | 2017 | 144 | 0.320 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 592 | 0.320 |
Why?
|
| Female | 22 | 2023 | 19873 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2008 | 58 | 0.310 |
Why?
|
| Glycolysis | 3 | 2018 | 66 | 0.310 |
Why?
|
| Gene Frequency | 4 | 2020 | 155 | 0.300 |
Why?
|
| Coronary Vessels | 1 | 2007 | 93 | 0.300 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2007 | 54 | 0.300 |
Why?
|
| Muscle Cells | 1 | 2006 | 12 | 0.290 |
Why?
|
| Ischemic Preconditioning, Myocardial | 2 | 2021 | 13 | 0.290 |
Why?
|
| Electrocardiography | 5 | 2020 | 154 | 0.290 |
Why?
|
| Transcription Factors | 4 | 2020 | 653 | 0.290 |
Why?
|
| Luminescent Proteins | 2 | 2006 | 74 | 0.280 |
Why?
|
| Blotting, Western | 3 | 2021 | 834 | 0.280 |
Why?
|
| Liver | 3 | 2021 | 447 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2020 | 638 | 0.270 |
Why?
|
| Aortic Diseases | 3 | 2017 | 26 | 0.260 |
Why?
|
| Ehlers-Danlos Syndrome | 2 | 2022 | 5 | 0.260 |
Why?
|
| Hyperthyroidism | 1 | 2004 | 5 | 0.250 |
Why?
|
| Hemodynamics | 3 | 2017 | 86 | 0.250 |
Why?
|
| Ultrasonic Therapy | 1 | 2003 | 5 | 0.240 |
Why?
|
| Smoking | 2 | 2013 | 903 | 0.230 |
Why?
|
| Sex Factors | 4 | 2019 | 859 | 0.230 |
Why?
|
| Muscle Fibers, Fast-Twitch | 1 | 2003 | 4 | 0.230 |
Why?
|
| Muscle Fibers, Slow-Twitch | 1 | 2003 | 7 | 0.230 |
Why?
|
| Quantitative Trait, Heritable | 2 | 2013 | 22 | 0.230 |
Why?
|
| Lipopolysaccharides | 1 | 2004 | 200 | 0.230 |
Why?
|
| Heart Atria | 1 | 2002 | 27 | 0.230 |
Why?
|
| Physical Endurance | 1 | 2003 | 18 | 0.230 |
Why?
|
| Risk Factors | 8 | 2019 | 3414 | 0.220 |
Why?
|
| Physical Conditioning, Animal | 1 | 2003 | 26 | 0.220 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2003 | 60 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2012 | 528 | 0.220 |
Why?
|
| Time Factors | 5 | 2019 | 1681 | 0.220 |
Why?
|
| Myoglobin | 1 | 2002 | 8 | 0.210 |
Why?
|
| Altitude | 1 | 2002 | 6 | 0.210 |
Why?
|
| Lipid Metabolism | 2 | 2013 | 109 | 0.210 |
Why?
|
| Lipids | 2 | 2013 | 222 | 0.210 |
Why?
|
| Models, Cardiovascular | 1 | 2021 | 53 | 0.200 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2021 | 65 | 0.200 |
Why?
|
| Green Fluorescent Proteins | 4 | 2014 | 200 | 0.190 |
Why?
|
| Aorta, Thoracic | 2 | 2017 | 24 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2014 | 157 | 0.180 |
Why?
|
| Genetics, Population | 3 | 2013 | 66 | 0.180 |
Why?
|
| Caveolin 1 | 2 | 2011 | 27 | 0.180 |
Why?
|
| Oxygen | 2 | 2013 | 193 | 0.180 |
Why?
|
| Muscle, Skeletal | 3 | 2015 | 257 | 0.170 |
Why?
|
| DNA | 3 | 2011 | 549 | 0.170 |
Why?
|
| Species Specificity | 1 | 2019 | 233 | 0.170 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2011 | 87 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 3 | 2005 | 430 | 0.170 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 35 | 0.160 |
Why?
|
| Risk Assessment | 2 | 2019 | 727 | 0.160 |
Why?
|
| United States | 9 | 2018 | 3894 | 0.160 |
Why?
|
| Fibroblasts | 3 | 2015 | 252 | 0.160 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2017 | 23 | 0.160 |
Why?
|
| Doxycycline | 1 | 2017 | 30 | 0.160 |
Why?
|
| Isoenzymes | 1 | 2018 | 149 | 0.160 |
Why?
|
| Middle Aged | 10 | 2023 | 9642 | 0.150 |
Why?
|
| Patient Readmission | 1 | 2018 | 74 | 0.150 |
Why?
|
| Protein Binding | 1 | 2020 | 913 | 0.150 |
Why?
|
| Drug Costs | 1 | 2017 | 28 | 0.150 |
Why?
|
| Gene Deletion | 3 | 2011 | 156 | 0.150 |
Why?
|
| Long QT Syndrome | 1 | 2016 | 12 | 0.150 |
Why?
|
| Heart Conduction System | 1 | 2016 | 14 | 0.150 |
Why?
|
| Infusions, Intravenous | 2 | 2009 | 48 | 0.150 |
Why?
|
| Genes, Reporter | 4 | 2006 | 132 | 0.150 |
Why?
|
| Gene Expression | 5 | 2015 | 639 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 77 | 0.140 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 147 | 0.140 |
Why?
|
| DNA Methylation | 1 | 2019 | 301 | 0.140 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2015 | 8 | 0.140 |
Why?
|
| Calcium | 1 | 2018 | 445 | 0.140 |
Why?
|
| Prothrombin Time | 1 | 2015 | 9 | 0.140 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2015 | 12 | 0.140 |
Why?
|
| Ultrasonography | 3 | 2005 | 115 | 0.130 |
Why?
|
| Blood Glucose | 2 | 2015 | 333 | 0.130 |
Why?
|
| Microspheres | 3 | 2003 | 45 | 0.130 |
Why?
|
| Rats | 5 | 2006 | 3261 | 0.130 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 132 | 0.130 |
Why?
|
| NF-kappa B | 2 | 2008 | 306 | 0.130 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 859 | 0.130 |
Why?
|
| Osteogenesis | 1 | 2014 | 31 | 0.120 |
Why?
|
| Aged | 7 | 2018 | 6448 | 0.120 |
Why?
|
| Phosphorylation | 2 | 2015 | 878 | 0.120 |
Why?
|
| Infant | 4 | 2017 | 1014 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 2 | 2022 | 183 | 0.120 |
Why?
|
| Transposases | 1 | 2013 | 8 | 0.120 |
Why?
|
| In Situ Hybridization | 2 | 2004 | 125 | 0.120 |
Why?
|
| Base Sequence | 2 | 2006 | 932 | 0.120 |
Why?
|
| Glycogen | 1 | 2013 | 17 | 0.120 |
Why?
|
| Oxidative Stress | 3 | 2011 | 874 | 0.120 |
Why?
|
| Organ Specificity | 2 | 2004 | 123 | 0.120 |
Why?
|
| Transgenes | 2 | 2003 | 57 | 0.120 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 57 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 245 | 0.120 |
Why?
|
| Child, Preschool | 4 | 2017 | 1318 | 0.120 |
Why?
|
| Insulin Resistance | 1 | 2015 | 177 | 0.120 |
Why?
|
| Genotype | 3 | 2020 | 641 | 0.110 |
Why?
|
| Reperfusion Injury | 1 | 2013 | 53 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2013 | 89 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 211 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2022 | 1961 | 0.110 |
Why?
|
| Tachycardia | 1 | 2012 | 11 | 0.110 |
Why?
|
| Genome, Human | 1 | 2013 | 112 | 0.110 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 195 | 0.110 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 143 | 0.110 |
Why?
|
| Cryosurgery | 1 | 2011 | 2 | 0.100 |
Why?
|
| Phenotype | 3 | 2020 | 650 | 0.100 |
Why?
|
| Adult | 8 | 2023 | 11034 | 0.100 |
Why?
|
| Adolescent | 6 | 2017 | 5035 | 0.100 |
Why?
|
| Endothelium | 1 | 2011 | 31 | 0.100 |
Why?
|
| Young Adult | 6 | 2017 | 4012 | 0.100 |
Why?
|
| Central Nervous System Stimulants | 1 | 2013 | 165 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2011 | 19 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 31 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2006 | 1534 | 0.100 |
Why?
|
| Flow Cytometry | 3 | 2011 | 392 | 0.100 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2011 | 91 | 0.090 |
Why?
|
| Aging | 2 | 2006 | 639 | 0.090 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 71 | 0.090 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 126 | 0.090 |
Why?
|
| Air Pollution | 1 | 2011 | 59 | 0.090 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 115 | 0.090 |
Why?
|
| Receptor, TIE-2 | 2 | 2011 | 2 | 0.090 |
Why?
|
| Smad3 Protein | 2 | 2022 | 12 | 0.090 |
Why?
|
| Alleles | 2 | 2016 | 284 | 0.090 |
Why?
|
| Linkage Disequilibrium | 3 | 2016 | 58 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 94 | 0.090 |
Why?
|
| Child | 4 | 2017 | 2875 | 0.090 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2011 | 26 | 0.090 |
Why?
|
| Femoral Artery | 1 | 2009 | 11 | 0.090 |
Why?
|
| MEDLINE | 2 | 2006 | 7 | 0.090 |
Why?
|
| Dextrans | 1 | 2009 | 17 | 0.090 |
Why?
|
| Integrases | 2 | 2011 | 27 | 0.090 |
Why?
|
| Pressure | 1 | 2009 | 36 | 0.090 |
Why?
|
| Selenoproteins | 1 | 2011 | 151 | 0.090 |
Why?
|
| Receptor, Endothelin A | 1 | 2008 | 3 | 0.090 |
Why?
|
| Receptor, Endothelin B | 1 | 2008 | 3 | 0.090 |
Why?
|
| Endothelins | 1 | 2008 | 6 | 0.090 |
Why?
|
| Receptors, Endothelin | 1 | 2008 | 7 | 0.090 |
Why?
|
| Phagocytosis | 1 | 2009 | 64 | 0.090 |
Why?
|
| Calcineurin | 1 | 2008 | 21 | 0.090 |
Why?
|
| Vitamin D | 1 | 2011 | 176 | 0.080 |
Why?
|
| Biological Transport | 1 | 2009 | 175 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 92 | 0.080 |
Why?
|
| Reactive Oxygen Species | 2 | 2007 | 416 | 0.080 |
Why?
|
| Mucins | 1 | 2008 | 33 | 0.080 |
Why?
|
| Fluorescent Dyes | 1 | 2009 | 173 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 90 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 94 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 122 | 0.080 |
Why?
|
| Adiponectin | 1 | 2008 | 52 | 0.080 |
Why?
|
| Th2 Cells | 1 | 2007 | 56 | 0.080 |
Why?
|
| Antioxidants | 1 | 2011 | 386 | 0.080 |
Why?
|
| Allergens | 1 | 2007 | 58 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 195 | 0.080 |
Why?
|
| Albumins | 2 | 2004 | 24 | 0.080 |
Why?
|
| Mitochondria, Heart | 1 | 2007 | 66 | 0.080 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2006 | 5 | 0.070 |
Why?
|
| Consensus Sequence | 1 | 2006 | 24 | 0.070 |
Why?
|
| Adenosine Triphosphate | 1 | 2007 | 180 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2005 | 1442 | 0.070 |
Why?
|
| Islets of Langerhans | 1 | 2006 | 9 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2007 | 160 | 0.070 |
Why?
|
| Isoproterenol | 1 | 2006 | 35 | 0.070 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2006 | 24 | 0.070 |
Why?
|
| Inflammation | 1 | 2011 | 577 | 0.070 |
Why?
|
| Prevalence | 3 | 2017 | 1425 | 0.070 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2006 | 46 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2022 | 1353 | 0.070 |
Why?
|
| Receptors, IgG | 1 | 2005 | 48 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 2333 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2007 | 420 | 0.070 |
Why?
|
| Macrophages | 2 | 2011 | 431 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2005 | 63 | 0.070 |
Why?
|
| Melatonin | 1 | 2006 | 78 | 0.070 |
Why?
|
| Heart Diseases | 1 | 2006 | 99 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2004 | 2 | 0.060 |
Why?
|
| Lipocalins | 1 | 2004 | 6 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2004 | 18 | 0.060 |
Why?
|
| Computer Systems | 1 | 2004 | 18 | 0.060 |
Why?
|
| Smoke | 1 | 2005 | 39 | 0.060 |
Why?
|
| Acute-Phase Proteins | 1 | 2004 | 14 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2005 | 147 | 0.060 |
Why?
|
| Health Status Disparities | 1 | 2011 | 583 | 0.060 |
Why?
|
| Software | 1 | 2006 | 204 | 0.060 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2004 | 28 | 0.060 |
Why?
|
| DNA Primers | 1 | 2005 | 269 | 0.060 |
Why?
|
| Databases, Bibliographic | 1 | 2004 | 9 | 0.060 |
Why?
|
| Natural Language Processing | 1 | 2004 | 10 | 0.060 |
Why?
|
| Triiodothyronine | 1 | 2004 | 30 | 0.060 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 34 | 0.060 |
Why?
|
| Smad2 Protein | 2 | 2015 | 9 | 0.060 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2005 | 127 | 0.060 |
Why?
|
| Fluorocarbons | 1 | 2004 | 19 | 0.060 |
Why?
|
| Information Storage and Retrieval | 1 | 2004 | 30 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2004 | 32 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2004 | 188 | 0.060 |
Why?
|
| Lung | 1 | 2006 | 413 | 0.060 |
Why?
|
| Recombination, Genetic | 1 | 2004 | 90 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2003 | 59 | 0.060 |
Why?
|
| Asthma | 1 | 2007 | 363 | 0.060 |
Why?
|
| Artificial Intelligence | 1 | 2004 | 63 | 0.060 |
Why?
|
| Echocardiography, Doppler | 1 | 2003 | 39 | 0.060 |
Why?
|
| Periodicals as Topic | 1 | 2004 | 48 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2003 | 38 | 0.060 |
Why?
|
| Myogenic Regulatory Factors | 1 | 2002 | 2 | 0.060 |
Why?
|
| Arteries | 1 | 2023 | 67 | 0.060 |
Why?
|
| Environmental Exposure | 1 | 2005 | 207 | 0.060 |
Why?
|
| Blotting, Northern | 1 | 2003 | 139 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2002 | 106 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 229 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 484 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 984 | 0.050 |
Why?
|
| Viral Proteins | 1 | 2004 | 172 | 0.050 |
Why?
|
| RNA | 1 | 2004 | 234 | 0.050 |
Why?
|
| Tibet | 1 | 2002 | 2 | 0.050 |
Why?
|
| Triglycerides | 2 | 2013 | 129 | 0.050 |
Why?
|
| Incidence | 2 | 2016 | 882 | 0.050 |
Why?
|
| Exons | 1 | 2002 | 80 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2002 | 101 | 0.050 |
Why?
|
| Hawaii | 2 | 2018 | 1878 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2017 | 1422 | 0.050 |
Why?
|
| Genomics | 1 | 2002 | 201 | 0.050 |
Why?
|
| Myeloid Cells | 2 | 2011 | 28 | 0.050 |
Why?
|
| Binding Sites | 1 | 2002 | 597 | 0.050 |
Why?
|
| Algorithms | 1 | 2004 | 435 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 165 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2020 | 70 | 0.050 |
Why?
|
| Microscopy, Confocal | 2 | 2014 | 210 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 901 | 0.050 |
Why?
|
| Molecular Chaperones | 1 | 2020 | 61 | 0.050 |
Why?
|
| Models, Animal | 2 | 2015 | 131 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 128 | 0.040 |
Why?
|
| Apoptosis | 1 | 2006 | 1317 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2020 | 197 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 459 | 0.040 |
Why?
|
| Elastin | 1 | 2017 | 37 | 0.040 |
Why?
|
| Matrix Metalloproteinases | 1 | 2017 | 44 | 0.040 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 5 | 0.040 |
Why?
|
| Aortic Aneurysm | 1 | 2017 | 5 | 0.040 |
Why?
|
| Lovastatin | 1 | 2017 | 10 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2017 | 269 | 0.040 |
Why?
|
| Simvastatin | 1 | 2017 | 28 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2016 | 24 | 0.040 |
Why?
|
| Heart Defects, Congenital | 1 | 2017 | 61 | 0.040 |
Why?
|
| Cell Line | 2 | 2015 | 1289 | 0.040 |
Why?
|
| Turner Syndrome | 1 | 2016 | 2 | 0.040 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2016 | 4 | 0.040 |
Why?
|
| Aorta, Abdominal | 1 | 2016 | 10 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 142 | 0.040 |
Why?
|
| Activin Receptors, Type I | 1 | 2015 | 4 | 0.040 |
Why?
|
| Dioxoles | 1 | 2015 | 6 | 0.040 |
Why?
|
| Activins | 1 | 2015 | 7 | 0.040 |
Why?
|
| Postpartum Period | 1 | 2016 | 59 | 0.040 |
Why?
|
| Organ Size | 1 | 2016 | 148 | 0.040 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2015 | 24 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2015 | 96 | 0.030 |
Why?
|
| Medicare | 1 | 2017 | 188 | 0.030 |
Why?
|
| AMP Deaminase | 1 | 2015 | 1 | 0.030 |
Why?
|
| Benzamides | 1 | 2015 | 76 | 0.030 |
Why?
|
| Nucleotides | 1 | 2015 | 33 | 0.030 |
Why?
|
| Ischemia | 1 | 2015 | 45 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 964 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2014 | 34 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2014 | 33 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2014 | 75 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 1007 | 0.030 |
Why?
|
| High-Energy Shock Waves | 1 | 2013 | 1 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2013 | 32 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2014 | 89 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2013 | 8 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 63 | 0.030 |
Why?
|
| DNA Transposable Elements | 1 | 2013 | 44 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2013 | 87 | 0.030 |
Why?
|
| Cardiotonic Agents | 1 | 2013 | 35 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 102 | 0.030 |
Why?
|
| Population Groups | 1 | 2013 | 56 | 0.030 |
Why?
|
| Metagenomics | 1 | 2012 | 32 | 0.030 |
Why?
|
| Endocrine System | 1 | 2011 | 12 | 0.030 |
Why?
|
| Tetracycline | 1 | 2011 | 17 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2011 | 39 | 0.030 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2011 | 5 | 0.030 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2011 | 5 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2011 | 49 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2011 | 31 | 0.030 |
Why?
|
| Microvessels | 1 | 2011 | 31 | 0.030 |
Why?
|
| Pregnancy | 1 | 2016 | 1503 | 0.030 |
Why?
|
| Cell Separation | 1 | 2011 | 91 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 185 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2011 | 65 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 43 | 0.020 |
Why?
|
| Microcirculation | 1 | 2011 | 39 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2011 | 61 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 707 | 0.020 |
Why?
|
| Pericytes | 1 | 2011 | 21 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 56 | 0.020 |
Why?
|
| Fibrosis | 1 | 2011 | 146 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 164 | 0.020 |
Why?
|
| Collagen | 1 | 2011 | 162 | 0.020 |
Why?
|
| Vitamins | 1 | 2011 | 91 | 0.020 |
Why?
|
| Computational Biology | 1 | 2012 | 275 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 445 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2013 | 613 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 2561 | 0.020 |
Why?
|
| Body Weight | 1 | 2011 | 404 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2011 | 196 | 0.020 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2007 | 7 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2011 | 366 | 0.020 |
Why?
|
| Interleukins | 1 | 2007 | 28 | 0.020 |
Why?
|
| Pulmonary Fibrosis | 1 | 2007 | 25 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2006 | 46 | 0.020 |
Why?
|
| Metalloproteases | 1 | 2006 | 16 | 0.020 |
Why?
|
| C-Peptide | 1 | 2006 | 6 | 0.020 |
Why?
|
| Hexokinase | 1 | 2006 | 9 | 0.020 |
Why?
|
| U937 Cells | 1 | 2005 | 27 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2006 | 115 | 0.020 |
Why?
|
| Serum Amyloid P-Component | 1 | 2005 | 20 | 0.020 |
Why?
|
| Avidin | 1 | 2005 | 5 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2011 | 1149 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 2006 | 129 | 0.020 |
Why?
|
| Acetylcholine | 1 | 2005 | 68 | 0.020 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2005 | 42 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2005 | 184 | 0.020 |
Why?
|
| Insulin | 1 | 2006 | 224 | 0.020 |
Why?
|
| Computing Methodologies | 1 | 2004 | 5 | 0.020 |
Why?
|
| Cattle | 1 | 2005 | 472 | 0.020 |
Why?
|
| Database Management Systems | 1 | 2004 | 19 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2004 | 30 | 0.020 |
Why?
|
| Semantics | 1 | 2004 | 26 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 282 | 0.010 |
Why?
|
| Rats, Zucker | 1 | 2003 | 22 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2005 | 287 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 528 | 0.010 |
Why?
|